1例卡瑞利珠单抗致甲状腺功能减退不良反应分析  

Analysis on A Case of Hypothyroidism Induced by Camrelizumab

作　　者：陈刚[1] 闫丽荣 王哲[1] 郭敏[1] CHEN Gang;YAN Lirong;WAGN Zhe;GUO Min(Department of Pharmacy,Ordos Central Hospital,Ordos,Inner Mongolia Autonomous Region,017000,China;Department of Pharmacy,Dongsheng District People’s Hospital,Ordos,Inner Mongolia Autonomous Region,017000,China)

机构地区：[1]鄂尔多斯市中心医院药剂科,内蒙古鄂尔多斯017000 [2]东胜区人民医院药剂科,内蒙古鄂尔多斯017000

出　　处：《肿瘤药学》2020年第1期125-128,共4页Anti-Tumor Pharmacy

摘　　要：1例63岁晚期肺癌男性患者使用卡瑞利珠单抗(200 mg、ivgtt q2w),12周后发生甲状腺功能减退,期间未使用其他药物,考虑与卡瑞利珠单抗有关。嘱患者口服补充甲状腺素,甲状腺功能指标逐渐恢复正常。A 63-year-old male with advanced lung cancer received camrelizumab(200 mg ivgtt q2w).After 12 weeks,the patient had hypothyroidism.Since the patient had no other drugs during the period,we considered that his hypothyroidism was associated with camrelizumab.The patient was given oral thyroxine supplementation and the thyroid function index gradually returned to normal.

关 键 词：卡瑞利珠单抗 甲状腺功能减退 药品不良反应 

分 类 号：R734.2[医药卫生—肿瘤] R730.6[医药卫生—临床医学]